Curaleaf Holdings Inc
TSX:CURA

Watchlist Manager
Curaleaf Holdings Inc Logo
Curaleaf Holdings Inc
TSX:CURA
Watchlist
Price: 1.13 CAD -3.42% Market Closed
Market Cap: 855.6m CAD
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one CURA stock under the Base Case scenario is 5.02 CAD. Compared to the current market price of 1.13 CAD, Curaleaf Holdings Inc is Undervalued by 77%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

CURA Relative Value
Base Case
5.02 CAD
Undervaluation 77%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

0.4
P/S
P/S
Price to Sales
0.4
vs History
96
vs Industry
82
Median 3Y
1.3
Median 5Y
2.2
Industry
2.5
Forward
0.5
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
Median 3Y
-7.2
Median 5Y
-9.4
Industry
21.8
Forward
-3.7
More Details
3.9
P/OCF
P/OCF
Price to OCF
3.9
vs History
75
vs Industry
49
Median 3Y
40.6
Median 5Y
32.5
Industry
16.6
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
Median 3Y
-7.2
Median 5Y
-9.5
Industry
24
More Details
0.8
P/B
P/B
Price to Book Value
0.8
vs History
96
vs Industry
66
Median 3Y
2.2
Median 5Y
2.4
Industry
2.1
More Details
0.8
EV/S
EV/S
Enterprise Value to Sales
0.8
vs History
96
vs Industry
70
Median 3Y
1.7
Median 5Y
2.8
Industry
2.7
Forward
1
More Details
1.7
EV/GP
EV/GP
Enterprise Value to Gross Profit
1.7
vs History
96
vs Industry
68
Median 3Y
3.7
Median 5Y
5.8
Industry
5.3
More Details
5
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
5
vs History
58
vs Industry
45
Median 3Y
10.5
Median 5Y
6.2
Industry
12.8
Forward
4.8
More Details
49.3
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
49.3
vs History
49
vs Industry
5
Median 3Y
51.9
Median 5Y
49.4
Industry
16.2
Forward
28
More Details
8.7
EV/OCF
EV/OCF
Enterprise Value to OCF
8.7
vs History
75
vs Industry
41
Median 3Y
51.5
Median 5Y
39.5
Industry
15.1
More Details
22.1
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
22.1
vs History
35
vs Industry
21
Median 3Y
22.2
Median 5Y
-29.4
Industry
17.7
More Details
0.5
EV/IC
EV/IC
Enterprise Value to IC
0.5
vs History
96
vs Industry
74
Median 3Y
1.1
Median 5Y
1.3
Industry
1.9
More Details

Multiples Across Competitors

CURA Competitors Multiples
Curaleaf Holdings Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Curaleaf Holdings Inc
TSX:CURA
854.8m CAD 0.4 -2.3 5 49.3
US
Eli Lilly and Co
NYSE:LLY
732.5B USD 14.9 66 35.4 38.7
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
373.5B USD 4.2 17.1 12.5 16.4
DK
Novo Nordisk A/S
CSE:NOVO B
2T DKK 6.4 18.7 12.9 14.8
CH
Roche Holding AG
SIX:ROG
202.7B CHF 3.4 24.5 9.2 10.8
CH
Novartis AG
SIX:NOVN
190.4B CHF 4.5 18.6 10.9 14.6
UK
AstraZeneca PLC
LSE:AZN
157.7B GBP 3.9 27.6 130.6 196.9
US
Merck & Co Inc
NYSE:MRK
203.6B USD 3.2 11.7 8.7 10.5
IE
Endo International PLC
LSE:0Y5F
163.5B USD 70.5 -56 261.3 655.3
US
Pfizer Inc
NYSE:PFE
143.5B USD 2.3 18.2 7.7 10.9
P/E Multiple
Earnings Growth PEG
US
Curaleaf Holdings Inc
TSX:CURA
Average P/E: 25.3
Negative Multiple: -2.3 		N/A N/A
US
Eli Lilly and Co
NYSE:LLY
66
49%
1.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
17.1
27%
0.6
DK
Novo Nordisk A/S
CSE:NOVO B
18.7
18%
1
CH
Roche Holding AG
SIX:ROG
24.5
32%
0.8
CH
Novartis AG
SIX:NOVN
18.6
17%
1.1
UK
AstraZeneca PLC
LSE:AZN
27.6
36%
0.8
US
Merck & Co Inc
NYSE:MRK
11.7
17%
0.7
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -56 N/A N/A
US
Pfizer Inc
NYSE:PFE
18.2
30%
0.6
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Curaleaf Holdings Inc
TSX:CURA
Average EV/EBITDA: 394.6
5
9%
0.6
US
Eli Lilly and Co
NYSE:LLY
35.4
30%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
12.5
7%
1.8
DK
Novo Nordisk A/S
CSE:NOVO B
12.9
13%
1
CH
Roche Holding AG
SIX:ROG
9.2
5%
1.8
CH
Novartis AG
SIX:NOVN
10.9
5%
2.2
UK
AstraZeneca PLC
LSE:AZN
130.6
10%
13.1
US
Merck & Co Inc
NYSE:MRK
8.7
8%
1.1
IE
E
Endo International PLC
LSE:0Y5F
261.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.7
2%
3.9
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Curaleaf Holdings Inc
TSX:CURA
Average EV/EBIT: 1 701.9
49.3
112%
0.4
US
Eli Lilly and Co
NYSE:LLY
38.7
32%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
16.4
13%
1.3
DK
Novo Nordisk A/S
CSE:NOVO B
14.8
14%
1.1
CH
Roche Holding AG
SIX:ROG
10.8
6%
1.8
CH
Novartis AG
SIX:NOVN
14.6
10%
1.5
UK
AstraZeneca PLC
LSE:AZN
196.9
23%
8.6
US
Merck & Co Inc
NYSE:MRK
10.5
11%
1
IE
E
Endo International PLC
LSE:0Y5F
655.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.9
10%
1.1

See Also

Summary
CURA intrinsic value, competitors valuation, and company profile.
DCF Valuation
CURA stock valuation using Discount Cash Flow valuation method.
Relative Valuation
CURA stock valuation using valuation multiples.
Wall Street Estimates
CURA price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
CURA stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 266,300+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.